The effect of tamoxifen and estrogen receptor status on survival in gastric carcinoma.
One hundred patients were entered in a randomized, controlled study of adjuvant tamoxifen therapy in gastric carcinoma. Estrogen receptor status was established by an immunohistologic method (ERD5) and 55.8% of the tumors were positive. Tamoxifen had no overall effect on survival, but there was a significant decrease in the survival time of the patients with ERD5-positive tumors. Estrogen receptor status (by the ERD5 method) is an independent prognostic factor in gastric cancer. Tamoxifen therapy does not prolong survival, and new therapeutic strategies require investigation.
Harrison
J D
JD
Department of Surgery and Pathology, University Hospital, Nottingham, England.
Morris
D L
DL
Ellis
I O
IO
Jones
J A
JA
Jackson
I
I
D002986:Clinical Trials as Topic; D005260:Female; D006651:Histocytochemistry; D006801:Humans; D007124:Immunoenzyme Techniques; D008113:Liver Neoplasms / Q000556:secondary; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D011379:Prognosis; D011897:Random Allocation; D011960:Receptors, Estrogen / Q000032:analysis*; D013274:Stomach Neoplasms / Q000032:analysis / Q000188:drug therapy* / Q000473:pathology; D013629:Tamoxifen / Q000627:therapeutic use*
D011960:Receptors, Estrogen; D013629:Tamoxifen